Variables

Infection (n = 54)

No infection (n = 44)

p

Gender (%)

Women

45 (83.3%)

36 (81.8%)

0.844

Men

9 (16.7%)

8 (18.2%)

Age groups (years)

<20

5 (9.3%)

3 (6.8%)

0.365

20 - 40

35 (64.8%)

25 (56.8%)

41 - 60

14 (25.9%)

14 (31.8%)

>60

0 (0%)

2 (4.5%)

Duration of follow-up (months)

28.72 ± 20.53

21.32 ± 19.70

0.074

Serum creatinine (mg/l)

22.55 ± 29.78

11.88 ± 11.20

0.027

Renal failure (%)

21 (38.9%)

6 (13.6%)

0.005

Nephrotic syndrome (%)

35 (64.8%)

22 (50.0%)

0.139

Leucopenia (%)

4 (7.4%)

6 (13.6%)

0.248

Lymphopenia (%)

21 (38.9%)

19 (43.2%)

0.667

ANA (%)

27 (93.1%)

24 (92.3%)

0.652

Anti-DNA antibodies (%)

16 (64.0%)

17 (68.0%)

0.765

C3 hypocomplementemia (%)

4 (57.1%)

1 (14.3%)

0.133

C4 hypocomplementemia (%)

4 (57.1%)

2 (28.6%)

0.296

Proliferatives classes (%)

37 (68.5%)

14 (31.8%)

0.001

HCQ (%)

44 (81.5%)

38 (86.4%)

0.515

MTP (%)

40 (74.1%)

18 (40.9%)

0.001

Prednisone (%)

54 (100.0%)

40 (90.9%)

0.038

MMF (%)

25 (46.3%)

13 (29.5%)

0.090

CYC (%)

19 (35.2%)

8 (18.2%)

0.061

AZA (%)

19 (35.2%)

8 (18.2%)

0.061